このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Intellia Therapeutics マネジメント

マネジメント基準チェック /24

Intellia Therapeutics'の CEO はJohn Leonardで、 Jan2018年に任命され、の在任期間は 6.58年です。の年間総報酬は$ 11.66Mで、 5.7%給与と94.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.82%を直接所有しており、その価値は€ 17.60M 。経営陣と取締役会の平均在任期間はそれぞれ5.9年と9.3年です。

主要情報

John Leonard

最高経営責任者

US$11.7m

報酬総額

CEO給与比率	5.7%
CEO在任期間	6.8yrs
CEOの所有権	0.8%
経営陣の平均在職期間	6.1yrs
取締役会の平均在任期間	9.5yrs

経営陣の近況

Recent updates

CEO報酬分析

Intellia Therapeutics の収益と比較して、John Leonard の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$509m
Mar 31 2024	n/a	n/a	-US$486m
Dec 31 2023	US$12m	US$660k	-US$481m
Sep 30 2023	n/a	n/a	-US$462m
Jun 30 2023	n/a	n/a	-US$453m
Mar 31 2023	n/a	n/a	-US$430m
Dec 31 2022	US$10m	US$630k	-US$474m
Sep 30 2022	n/a	n/a	-US$442m
Jun 30 2022	n/a	n/a	-US$400m
Mar 31 2022	n/a	n/a	-US$369m
Dec 31 2021	US$10m	US$600k	-US$268m
Sep 30 2021	n/a	n/a	-US$229m
Jun 30 2021	n/a	n/a	-US$185m
Mar 31 2021	n/a	n/a	-US$149m
Dec 31 2020	US$4m	US$580k	-US$134m
Sep 30 2020	n/a	n/a	-US$120m
Jun 30 2020	n/a	n/a	-US$116m
Mar 31 2020	n/a	n/a	-US$109m
Dec 31 2019	US$904k	US$559k	-US$100m
Sep 30 2019	n/a	n/a	-US$90m
Jun 30 2019	n/a	n/a	-US$89m
Mar 31 2019	n/a	n/a	-US$86m
Dec 31 2018	US$10m	US$550k	-US$85m
Sep 30 2018	n/a	n/a	-US$90m
Jun 30 2018	n/a	n/a	-US$83m
Mar 31 2018	n/a	n/a	-US$76m
Dec 31 2017	US$3m	US$396k	-US$68m

報酬と市場: Johnの総報酬 ($USD 11.66M ) は、 German市場 ($USD 1.59M ) の同規模の企業の平均を上回っています。

報酬と収益: Johnの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

John Leonard (67 yo)

6.8yrs

在職期間

US$11,657,262

報酬

Dr. John M. Leonard, M. D. is an Executive Partner at Tyree & D'Angelo Partners. He serves as Director at 3T Biosciences, Inc. since October 2022. He has been Independent Director at IQVIA Holdings Inc. si...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
John Leonard	President	6.8yrs	US$11.66m	0.82% $ 13.4m
Laura Sepp-Lorenzino	Executive VP & Chief Scientific Officer	5.4yrs	US$4.19m	0.019% $ 311.3k
James Basta	Executive VP	3.3yrs	US$3.99m	0.017% $ 285.2k
David Lebwohl	Executive VP & Chief Medical Officer	4.5yrs	US$4.26m	0.029% $ 471.4k
Nessan Bermingham	Founder & Member of Scientific Advisor Board	10.4yrs	US$11.27m	データなし
Rachel Haurwitz	Co-Founder	10.4yrs	US$311.57k	データなし
Andrew May	Founder and Member of Scientific Advisor Board	no data	データなし	データなし
Jennifer Doudna	Founder & Member of Scientific Advisor Board	no data	データなし	データなし
Derrick Rossi	Founder & Member of Scientific Advisor Board	no data	データなし	データなし
Rodolphe Barrangou	Founder & Member of Scientific Advisor Board	no data	データなし	データなし
Luciano Marraffini	Founder & Member of Scientific Advisor Board	no data	データなし	データなし
Erik Sontheimer	Founder & Member of Scientific Advisor Board	no data	データなし	データなし

6.1yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: 38Iの経営陣は経験豊富で経験豊富です（平均在職期間は5.9年）。

取締役

名称	ポジション	在職期間	報酬	所有権
John Leonard	President	10.3yrs	US$11.66m	0.82% $ 13.4m
Nessan Bermingham	Founder & Member of Scientific Advisor Board	no data	US$11.27m	データなし
Andrew May	Founder and Member of Scientific Advisor Board	no data	データなし	データなし
Jennifer Doudna	Founder & Member of Scientific Advisor Board	9.5yrs	データなし	データなし
Derrick Rossi	Founder & Member of Scientific Advisor Board	9.5yrs	データなし	データなし
Rodolphe Barrangou	Founder & Member of Scientific Advisor Board	no data	データなし	データなし
Luciano Marraffini	Founder & Member of Scientific Advisor Board	no data	データなし	データなし
Erik Sontheimer	Founder & Member of Scientific Advisor Board	no data	データなし	データなし
Arthur Krieg	Member of Scientific Advisory Board	no data	データなし	データなし
Beverly Davidson	Member of Scientific Advisory Board	9.8yrs	データなし	データなし
Franciscus A. G. Verwiel	Independent Chairman of the Board	7.3yrs	US$499.94k	0.010% $ 164.2k
William Chase	Independent Director	1.5yrs	US$996.21k	0.0067% $ 109.3k

9.5yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: 38Iの取締役会は経験豊富であると考えられます ( 9.3年の平均在任期間)。

Intellia Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Intellia Therapeutics, Inc. Announces Chief Financial Officer Changes

Intellia Therapeutics, Inc. Announces Executive Changes

Intellia Therapeutics, Inc. Names Brian Goff to its Board of Directors

Intellia Therapeutics, Inc., Annual General Meeting, Jun 12, 2024

President recently sold €519k worth of stock

Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees

Recent updates

Second quarter 2024 earnings released: US$1.52 loss per share (vs US$1.40 loss in 2Q 2023)

Intellia Therapeutics, Inc. Receives Authorization to Initiate Phase 1/2 Clinical Trial of Ntla-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

Blueallele Corporation Files Lawsuit for Patent Infringement Against Intellia Therapeutics, Inc., for the Unauthorized Use of Blueallele’S Patented Bi-Directional Insertion Templates

Intellia Therapeutics, Inc. Announces Chief Financial Officer Changes

Intellia Therapeutics, Inc. Announces Executive Changes

Intellia Therapeutics to Present the First-Ever Clinical Data from Patients Redosed with an Investigational in Vivo CRISPR Gene Editing Therapy At the Peripheral Nerve Society Annual Meeting 2024

Intellia Therapeutics, Inc. Names Brian Goff to its Board of Directors

Intellia Therapeutics, Inc. Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002

First quarter 2024 earnings released: US$1.13 loss per share (vs US$1.18 loss in 1Q 2023)

Intellia Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Intellia Therapeutics, Inc., Annual General Meeting, Jun 12, 2024

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

New minor risk - Shareholder dilution

Intellia Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $375.727167 million.

Full year 2023 earnings released: US$5.42 loss per share (vs US$6.16 loss in FY 2022)

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

President recently sold €519k worth of stock

Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees

Third quarter 2023 earnings released: US$1.38 loss per share (vs US$1.49 loss in 3Q 2022)

New minor risk - Share price stability

Intellia Therapeutics, Inc. Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 At the 4th International ATTR Amyloidosis Meeting

Insufficient new directors

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Second quarter 2023 earnings released: US$1.40 loss per share (vs US$1.33 loss in 2Q 2022)

Intellia Therapeutics, Inc. Appoints Eliana Clark, Phd, Executive Vice President and Chief Technical Officer

Intellia Therapeutics, Inc. Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Announces Resignation of Jean-François Formela as Board Member

First quarter 2023 earnings released: US$1.18 loss per share (vs US$1.97 loss in 1Q 2022)

Full year 2022 earnings released: US$6.16 loss per share (vs US$3.78 loss in FY 2021)

President recently sold €234k worth of stock

Intellia Therapeutics Presents New Interim Data from First-In-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001

Third quarter 2022 earnings released: US$1.49 loss per share (vs US$0.97 loss in 3Q 2021)

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

Intellia Therapeutics, Inc. to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema At the 2022 Bradykinin Symposium

Second quarter 2022 earnings released: US$1.33 loss per share (vs US$1.01 loss in 2Q 2021)

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announces Additional Positive Interim Data from an Ongoing Phase 1 Study of Their Lead Investigational in Vivo Genome Editing Candidate, NTLA-2001

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

First quarter 2022 earnings released: US$1.97 loss per share (vs US$0.69 loss in 1Q 2021)

Intellia Therapeutics, Inc. Names Muna Bhanji to Its Board of Directors

Intellia Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for Treatment of Acute Myeloid Leukemia

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Intellia Therapeutics, Inc. (NasdaqGM : NTLA) acquired Rewrite Therapeutics, Inc. for $200 million.

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy

Third quarter 2021 earnings released: US$0.97 loss per share (vs US$0.47 loss in 3Q 2020)

Intellia Therapeutics, Inc. announces U.S. Food and Drug Administration accept the investigational new drug (IND) application for NTLA-5001

Second quarter 2021 earnings released: US$1.01 loss per share (vs US$0.61 loss in 2Q 2020)

Intellia Therapeutics, Inc.(NasdaqGM:NTLA) dropped from Russell 3000E Index

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.63 loss in 1Q 2020)

Intellia Therapeutics, Inc. Announces the Presentation of New Data from Its CRISPR/Cas9 Platform

Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium

New 90-day low: €37.50

Full year 2020 earnings released: US$2.40 loss per share (vs US$2.11 loss in FY 2019)

Revenue misses expectations

New 90-day high: €60.00

Intellia Therapeutics, Inc. Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency

New 90-day high: €41.59

Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 in Vivo Sickle Cell Disease Treatments

Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis

Revenue beats expectations

Third quarter 2020 earnings released: US$0.47 loss per share

マネジメント基準チェック /24